Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection

Genes and Immunity

Volumn 8, Issue 3, 2007, Pages 181-192

  Neumann Haefelin, C ^a   Thimme, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; VIRUS PROTEIN; VIRUS RNA;

ANTIGEN FUNCTION; BINDING AFFINITY; CELLULAR IMMUNITY; DISEASE COURSE; GENETIC ASSOCIATION; GENETIC REGULATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBIOLOGY; METABOLIC CLEARANCE RATE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTECTION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS MUTATION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; HEPACIVIRUS; HEPATITIS C; HLA-B27 ANTIGEN; HUMANS; IMMUNOGENETICS; KILLER CELLS, NATURAL; MALE; MODELS, IMMUNOLOGICAL; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

HEPATITIS C VIRUS;

EID: 34247574266     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364368     Document Type: Review

References (116)

1. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19.
2. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-938.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
4. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004; 39: 1469-1475.
5. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-941.
6. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2): 3-8.
7. Dustin LB, Rice CM. Flying under the radar: The immunobiology of hepatitis C. Annu Rev Immunol 2007; 25: 71-99.
8. Parkin J, Cohen B. An overview of the immune system. Lancet 2001; 357: 1777-1789.
9. Diepolder HM, Zachoval R, Hoffmann RM, Werenga EA, Santantonio T, Jung MC et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-1007.
10. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-714.
11. Gruener NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 1528-1536.
12. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P et al. Analysis of successful immune responses in persons infected with hepatitis C vinis. J Exp Med 2000; 191: 1499-1512.
13. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Arad Sci USA 2002; 99: 15661-15668.
14. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-449.
15. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406.
16. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005; 42: 104-112.
17. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655.
18. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-662.
19. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-952.
20. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R. T cell response in hepatitis C virus infection. J Clin Virol 2005; 32: 75-85.
21. Thimme R, Lohmann V, Weber F. A target on the move: Innate and adaptive immune escape strategies of hepatitis C virus. Antivir Res 2006; 69: 129-141.
22. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714.
23. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005; 79 7860-7867.
24. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004; 113: 963-972.
25. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38: 1437-1448.
26. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062-1071.
27. Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005; 79: 7852-7859.
28. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 885-895.
29. Fanning LJ, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F. Viral clearance in hepatitis C (1b) infection: Relationship with human leukocyte antigen class II in a homogeneous population. Hepatology 2000; 31: 1334-1337.
30. Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: Spontaneous viral clearance and chronic HCV infection. Gut 2001; 49: 423-430.
31. Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol 1999; 30: 979-983.
32. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004; 40: 108-114.
33. McKiernan SM, Hagan R, Curry M, McDonald GS, Nolan N, Crowley J et al. The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology 2000; 118: 1124-1130.
34. Lever AM, Jeang KT. Replication of human immunodeficiency virus type 1 from entry to exit. Int J Hematol 2006; 84: 23-30.
35. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489-504.
36. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 2003; 9: 861-866.
37. Lichterfeld M, Yu XG, Le Gall S, Altfeld M. Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: At the crossroads of viral and host genetics. Trends Immunol 2005; 26 166-171.
38. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001; 410: 980-987.
39. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.J Virol 1994; 68: 4650-4655.
40. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189: 991-998.
41. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998; 72: 164-169.
42. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857-860.
43. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T Cell response against HIV-1. PLoS Med 2006; 3: E403.
44. Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 2002; 76: 8690-8701.
45. Draenert R, Allen TM, Liu Y, Wrin T, Chappey C, Verrill CL et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med 2006; 203: 529-539.
46. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54: 535-551.
47. Stephens HA. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol 2005; 26: 41-47.
48. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432: 769-775.
49. Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006; 176: 4094-4101.
50. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic pepticles. Nature 1988; 336: 484-M7.
51. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3 212-217.
52. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193: 375-386.
53. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412: 334-338.
54. Allen RL, O'Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999; 162: 5045-5048.
55. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 2001; 167: 5543-5547.
56. Roddis M, Carter RW, Sun MY, Weissensteiner T, McMichael AJ, Bowness P et al. Fully functional HLA B27-restricted CD4+ as well as CD8+ T cell responses in TCR transgenic mice. J Immunol 2004; 172 155-161.
57. Klein MR, van der Burg SH, Hovenkamp E, Holwerda AM, Drijfhout JW, Mehef CJ et al. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol 1998; 79 (Part 9): 2191-2201.
58. Goulder PJ, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B et al. Novel, cross-restricted, conserved, and i mmunodominant cytotoxic T lymphocyte epitopes in slow progressors in HTV type 1 infection. AIDS Res Hum Retroviruses 1996; 12: 1691-1698.
59. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10: 282-289.
60. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 2004; 199: 905-915.
61. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80: 3617-3623.
62. Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ et al. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS 2002; 16: 961-972.
63. Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M et al. The differential ability of HLA B*5701 + long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J Virol 2003; 77: 6889-6898.
64. Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006; 203: 1357-1369.
65. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L et al. HLA B*701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97: 2709-2714.
66. Scherer A, Frater J, Oxenius A, Agudelo, J, Price DA, Gunthard HF et al. Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci USA 2004; 101 12266-12270.
67. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9: 928-935.
68. Altfeld M, Allen TM. Hitting HIV where it hurts: An alternative approach to HIV vaccine design. Trends Immunol 2006; 27: 504-510.
69. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ et al. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283: 1748-1752.
70. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, Karita E et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999; 15: 317-324.
71. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76: 4792-4797.
72. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006; 43: 563-572.
73. Timm J, Lauer GM, Kavanagh DG, Sheridan I. Kim AY, Lucas M et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004; 200: 1593-1604.
74. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med 2005; 201: 1753-1759.
75. Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 2006; 80: 11094-11104.
76. Altman JD, Feinberg MB. HIV escape: There and back again. Nat Med 2004; 10: 229-230.
77. Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, Hartman K et al. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med 2004; 200 307-319.
78. Patel K, Norris S, Lebeck L, Feng A, Clare M, Piankc, S et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 2006; 43: 241-249.
79. Williams AP, Bateman AR, Khakoo SI. Hanging in the balance. KIR and their role in disease. Mol Interv 2005; 5: 226-240.
80. Khakoo SI, Thio CL, Martin W, Brooks CR, Gao X, Astemborski J et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-874.
81. Parham P. Immunology. NK cells lose their inhibition. Science 2004; 305: 786-787.
82. Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease. J Exp Med 2005; 201: 1025-1029.
83. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein e2 to CD81 inhibits natural killer cell functions. J Exp Med 2002; 195: 43-50.
84. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195 35-42.
85. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31: 429-434.
86. Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, Buchbinder S et al. KIR/HLA pleiotropism: Protection against both HIV and opportunistic infections. PLoS Pathogen 2006; 2: E79.
87. Jennes W, Verheyden S, Demanet C, Adje-Toure CA, Vuylsteke B, Nkengasong JN et al. Cutting edge: Resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006; 177: 6588-6592.
88. Gaudieri S, DeSantis D, McKinnon E, Moore C, Nolan D, Witt CS et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005; 6: 683-690.
89. Godkin A, Jeanguet N, Thursz M, Openshaw P, Thomas H. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. Eur J Immunol 2001; 31: 1438-1446.
90. Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002; 76: 12584-12595.
91. Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003; 112: 831-842.
92. Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J et al. Differential CD4 and CD8 T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33: 267-276.
93. Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: Correlation with clinical disease stages. Hepatology 2002; 35: 190-198.
94. Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005; 175: 3603-3613.
95. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5: 237-245.
96. Hong X, Yu RB, Sun NX, Wang B, Xu YC, Wu GL. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: A meta-analysis. World J Gastroenterol 2005; 11: 7302-7307.
97. Azocar J, Clavijo OP, Yunis EJ. MHC class II genes in HCV viral clearance of hepatitis C infected Hispanic patients. Hum Immunol 2003; 64: 99-102.
98. Lechmann M, Schneider EM, Giers G, Kaiser R, Dumoulin FL, Sauerbruch T et al. Increased frequency of the HLA-DR15 (Bl*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest 1999; 29: 337-343.
99. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998; 29: 207-213.
100. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184: 16-21.
101. Gerlach JT, Ulsenheimer A, Gruner NH, Jung MC, Schraut W, Schirren CA et al. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J Virol 2005; 79: 12425-12433.
102. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71: 6011-6019.
103. Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: Implications for vaccine development. Hepatology 1999; 30: 1088-1098.
104. Harcourt GC, Lucas M, Sheridan I, Barnes E, Phillips R, Klenerman P. Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. J Viral Hepat 2004; 11: 324-331.
105. Harcourt G, Hellier S, Bunce M, Satsangi J, Collier J, Chapman R et al. Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat 2001; 8: 174-179.
106. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37: 577-589.
107. Ulsenheimer A, Lucas M, Seth NP, Tilman Gerlach J, Gruener NH, Loughry A et al. Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. J Viral Hepat 2006; 13: 708-714.
108. Scotto G, Fazio V, D'Alessandro G, Monno L, Saracino A, Palumbo E et al. Association between HLA class II antigens and hepatitis C virus infection. J Biol Regul Homeost Agents 2003; 17: 316-321.
109. Yenigun A, Durupinar B. Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J Virol 2002; 76: 1787-1789.
110. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354: 2119-2124.
111. Minton EJ, Smillie D, Neal KR, Irving WL, Underwood JC, James V. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis 1998; 178: 39-44.
112. Mangia A, Gentile R, Cascavilla I, Margaglione M, Villani MR, Stella F et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999; 30: 984-989.
113. Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998; 28 1-7.
114. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675-1681.
115. Wawrzynowicz-Syczewska M, Underhill JA, Clare MA, Boron-Kaczmarska A, McFarlane IG, Donaldson PT. HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland. Liver 2000; 20: 234-239.
116. Tibbs C, Donaldson P, Underhill J, Thomson L, Manabe K, Williams R. Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in Northern European Caucasoids. Hepatology 1996; 24: 1342-1345.